Saronic Biotechnology, Inc. Founded by physicians and research scientists with expertise in oncology, viral hepatitis, and immunology, Saronic Biotechnology has developed a highly promising cellular immunotherapy for hepatocellular carcinoma (HCC), the most common primary liver cancer and the third leading cause of cancer-related mortality worldwide. Their breakthrough product, SBI1997, has shown unprecedented results in preclinical models, demonstrating the potential to decrease the likelihood of cancer recurrence, shrink existing tumors, and extend the lives of HCC patients.

With a focus on research and development, the brand is dedicated to advancing the field of immunotherapy to provide effective treatments for liver cancer. Led by a management team with extensive experience, Saronic Biotechnology is at the forefront of developing innovative solutions to combat this devastating disease. Contact them today for more information and join their mission to transform the landscape of liver cancer treatment